Article

LC-MS/MS determination of verapamil in human plasma and its application in bioequivalence evaluation

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

OBJECTIVE: To establish a LC-MS/MS method for determination of verapamil in human plasma. METHODS: Thermo Hypurity C 18 column (2.1 mm × 150 mm, 5 μm) was used in the experiment. The column temperature was set at 40°C. 10 mmol · L -1 ammonium (including 0.1% ammonium formate)-acetonitrile (35:65) was used as the mobile phase and the flow rate was 0.3 mL · min -1. The sample room temperature was set at 15°C and the injection volume was 10 μL. ESI source and positive ion scan were used, verapamil and the internal standard imipramine were monitored at (m/z) 455.0 → 165.0 and (m/z) 281→86.0, respectively. RESULTS: The calibration curve of verapamil was linear in the range of 0.4575-234.20 ng · mL -1, and the detection limit for verapamil was about 0.1 ng · mL -1. The method had high sensitivity, stability and specificity and had been used for the pharmacokinetic study of verapamil in vivo successfully. CONCLUSION: The method is simple, accurate and repetitive for the determination of verapamil in human plasma and suitable for pharmacokinetic study.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

Article
A high throughput and sensitive liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method has been developed and validated for the determination of flunarizine in human plasma. Liquid‐liquid extraction under acidic conditions was used to extract flunarizine and flunarizine‐d8 from 100 μL human plasma. The mean extraction recovery obtained for flunarizine was 98.85% without compromising the sensitivity of the method. The chromatographic separation was performed on Hypersil Gold C18 (50 × 2.1 mm, 3 μm) column using methanol: 10 mM ammonium formate, pH 3.0 (90:10, v/v) as the mobile phase. A tandem mass spectrometer (API‐5500) equipped with an electrospray ionization (ESI) source in the positive ion mode was used for detection of flunarizine. Multiple reaction monitoring was selected for quantitation using the transitions, m/z 405.2→203.2 for flunarizine and m/z 413.1 →203.2 for flunarizine‐d8. The validated concentration range was established from 0.10‐100 ng/mL. The accuracy (96.1‐103.1 %), intra‐batch and inter‐batch precision (% CV≤ 5.2) were satisfactory and the drug was stable in human plasma under all tested conditions. The method was used to evaluate the pharmacokinetics of 5 mg and 10 mg flunarizine tablet formulation in 24 healthy subjects. The pharmacokinetic parameters Cmax and AUC were dose‐proportional.
Article
Full-text available
Both verapamil pharmacokinetics and electrocardio graphic changes in 10 Chinese volunteers were studied after po 240 mg of verapamil sustained release tablet. A one-compartment model with zero-order absorption gave a better fitting to concentration--time data with values of r2 > 0.96. The main pharmacokinetic parameters obtained were: Tmax, 5.9 +/- 1.6 h; Cmax, 118.9 +/- 37.2 micrograms.L-1; T1, 5.4 +/- 1.5 h; k0, 30.5 +/- 17.5 micrograms.L-1.h-1; T1/2, 10.8 +/- 4.9 h; MRT, 15.4 +/- 3.2 h and AUC. 1.96 +/- 0.82 mg.h.L-1. There were significant prolongations of PR intervals after dose. Relationships between PR interval changes and plasma concentrations of verapamil were better fitted to sigmoidal model, with r2 > 0.98. The corresponding pharmacodynamic parameters were estimated. EC50, 64.6 +/- 16.9 micrograms.L-1, Emax, 54 +/- 11 ms and s, 1.68 +/- 0.66.
Article
Full-text available
An analytical method based on liquid chromatography with positive ion electrospray ionization (ESI) coupled to tandem mass spectrometry detection (LC-MS/MS) was developed for the determination of Verapamil in human plasma using Metoprolol as the internal standard. The analyte and internal standard were extracted from the plasma samples by liquid-liquid extraction and chromatographed on a C(8) analytical column. The mobile phase consisted of methanol-water (70:30; v/v)+12 mM formic acid. The method had a chromatographic total run time of 3.5 min and was linear within the range 1.00-500 ng/mL. Detection was carried out on a Micromass Quattro Ultima tandem mass spectrometer by multiple reaction monitoring (MRM). The intra-run imprecision was less than 5.1% calculated from the quality control (QC) samples, and 16.3% from the limit of quantification (LOQ). The accuracy determined from QC samples were between 92.9 and 103.1%, and 95.2 and 115.3% from LOQ. Concerning the inter-batch analysis, the imprecision was less than 5.8% and 17.3% from QC samples and LOQ, respectively. The accuracy varied between 98.2 and 100.8% from QC and it was 103.1% from LOQ. The protocol herein described was employed in a bioequivalence study of two tablet formulations of Verapamil.
Article
OBJECTIVE: To develop a method for the determination of verapamil and its primary metabolite norverapamil in plasma. METHODS: HPLC with reversed-phase column C18 and fluorescence detection excitation at 275 nm and emission at 310 nm was described. A mixture of pH 3.0 acetate buffer-acetonitrile-triethylamine (70:35:0.4) was used as the mobile phase. Gallopamil was used as the internal standard. RESULTS: All compounds were eluted as separate symmetrical peaks and no interfering peaks appeared. No interference from endogenous blood constituents was observed. CONCLUSION: We developed a specific, sensitive, simple and reproducible HPLC method for the determination of verapamil and one of its main metabolites (norverapamil) in blood.
Article
A sensitive high-performance liquid chromatographic assay suitable for the simultaneous determination of verapamil (I) and its major active metabolite norverapamil (II) in human plasma is described. After adding internal standard ethmosine, plasma samples were extracted using a mixture of n-hexane and n-butyl alcohol (12:1) to give mean recoveries of > 92% of both I, and II. The extracts were chromatographed on a C18 reversed phase column with a mobile phase composed of methanol, water and triethylamine (67: 33: 0.4, pH 6.7), with UV (lambda, 279 nm) detection. The calibration curves were linear over a wide range of concentrations (25-1000 ng.ml-1), and the limits of determination was 2.5 ng.ml-1 for I and 5.0 ng.ml-1 for II. The method showed good precision: the within-day RSD were < 7.6% for both I and II; the day-to-day RSD were < 8.6% for both I and II. Using this assay, plasma concentrations of both I and II were simultaneously determined in six volunteers after a single oral dose of 120 mg of verapamil.HCl.
Article
An analytical method has been developed to determine simultaneously plasma concentration of the enantiomers of verapamil and its major metabolite, norverapamil, using capillary zone electrophoresis. Trimethyl-beta-cyclodextrin was selected as chiral selector. Good separation was achieved under the conditions as below: Running electrolyte was pH 2.5, 60 mmol.L-1 phosphate buffer containing 60 mmol.L-1 trimethyl-beta-cyclodextrin; capillary: 30 cm x 75 microns (ID), coated; setpoint of capillary temperature: 20 degrees C; detector: UV 200 nm; injection: electromigration at 12 kV for 7 s; running voltage: 14 kV. Solvent of sample was doubly deionized water. The migration times of enantiomers were less than 12 min. The good linear range was from 300.0 ng.ml-1 to 2.50 ng.ml-1. Relative standard deviations of assay accuracy and precision were less than 12%. It fits for routine therapeutic monitoring as it is highly efficient, rapid, sensitive, with less solvent and sample consumption and automation.
Article
A stereoselective bioanalytical method for the simultaneous quantification of the enantiomers of verapamil and its active main metabolite norverapamil in human plasma has been developed and validated. The samples were analysed by liquid chromatography-electrospray-tandem mass spectrometry (LC-ESI-MS/MS) in the Selected Reaction Monitoring (SRM) mode using a deuterated internal standard. The stationary phase used for the chiral separation was a Chiral-AGP. The enantiomers of verapamil were selectively detected from those of norverapamil by the mass spectrometer due to different molecular masses, although there was a chromatographic co-elution. Thus, time-consuming procedures like achiral preseparation or chemical derivatisation could be avoided. Higher detection sensitivity than earlier published methods based on fluorescence detection was obtained, although a mobile phase of high water-content and high flow-rate was introduced into the electrospray interface (85% aqueous ammonium acetate pH 7.4 +15% acetonitrile at 0.6 ml/min). The enantiomers of verapamil and norverapamil could be quantified at levels down to 50 pg and 60 pg/500 microl plasma sample, respectively, with R.S.D. in the range of 3.6-7.8%. The presented method was successfully applied to an in vivo intestinal absorption and bioavailability study in humans, using the Loc-I-Gut method.